Trials / Completed
CompletedNCT03306303
Association Between Plasma Melatonin and No-reflow
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,700 (actual)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.
Conditions
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2017-10-11
- Last updated
- 2017-10-11
Source: ClinicalTrials.gov record NCT03306303. Inclusion in this directory is not an endorsement.